Try
Denali Therapeutics Inc.
DNLIUnited States
35 filed reports · 407 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
35 reports · Mar 2018 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 26 | 3,745 | Mar 2018 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 8 | 3,194 | Dec 2018 to Dec 2025 |
| Current · 8-KSEC EDGAR | 1 | 2 | Jun 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 325 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 6, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 190 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 805 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 213 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 11, 2025 | 154 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 164 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 27, 2025 | 380 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 137 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 1, 2024 | 113 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 115 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 28, 2024 | 328 | Open |
Financial data
407 concepts · 6,941 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial392 concepts · 6,772 facts · Dec 2016 to Jul 2026
- Cash and cash equivalents at carrying value49 · Dec 2016 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents49 · Dec 2016 to Jun 2026
- Allocated share based compensation expense48 · Dec 2016 to Jun 2026
- Comprehensive income net of tax48 · Dec 2016 to Jun 2026
- Increase decrease in accounts payable48 · Dec 2016 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities48 · Dec 2016 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets48 · Dec 2016 to Jun 2026
- Net cash provided by used in investing activities48 · Dec 2016 to Jun 2026
- Net income loss48 · Dec 2016 to Jun 2026
- Operating income loss48 · Dec 2016 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax48 · Dec 2016 to Jun 2026
- Payments to acquire marketable securities48 · Dec 2016 to Jun 2026
- Payments to acquire property plant and equipment48 · Dec 2016 to Jun 2026
- Proceeds from sale and maturity of marketable securities48 · Dec 2016 to Jun 2026
- Research and development expense48 · Dec 2016 to Jun 2026
- Restricted cash and cash equivalents noncurrent48 · Dec 2016 to Jun 2026
- Share based compensation48 · Dec 2016 to Jun 2026
- General and administrative expense (US GAAP)47 · Dec 2016 to Mar 2026
- Operating expenses (US GAAP)47 · Dec 2016 to Mar 2026
- Share based compensation arrangement by share based payment award options outstanding number46 · Dec 2016 to Jun 2026
- Share based compensation arrangement by share based payment award options outstanding weighted average exercise price46 · Dec 2016 to Jun 2026
- Stockholders equity (US GAAP)46 · Dec 2016 to Jun 2026
- Net cash provided by used in financing activities45 · Dec 2016 to Jun 2026
- Net cash provided by used in operating activities45 · Dec 2016 to Jun 2026
Segment14 concepts · 167 facts · Dec 2022 to Jun 2026
- Therapeutics Segment38 · Dec 2022 to Jun 2026
- Income loss attributable to parent14 · Dec 2022 to Jun 2026
- Interest and other income14 · Dec 2022 to Jun 2026
- Operating income loss14 · Dec 2022 to Jun 2026
- Other research and development expense14 · Dec 2022 to Jun 2026
- Research and development expense14 · Dec 2022 to Jun 2026
- General and administrative expense (US GAAP)13 · Dec 2022 to Mar 2026
- Operating expenses (US GAAP)13 · Dec 2022 to Mar 2026
- Other general and administrative expense13 · Dec 2022 to Mar 2026
- Disposal group not discontinued operation gain loss on disposal10 · Dec 2022 to Dec 2025
- Revenue4 · Dec 2022 to Dec 2025
- Costs and expenses2 · Jun 2025 to Jun 2026
- Other selling general and administrative expense2 · Jun 2025 to Jun 2026
- Selling general and administrative expense2 · Jun 2025 to Jun 2026
Guidance1 concepts · 2 facts · Aug 2026
- Revenue Guidance2 · Aug 2026
Segments
167 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 167 facts
- Therapeutics167 · Dec 2022 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.